对比增强乳腺X线摄影替代乳腺MRI用于乳腺癌局部分期的成本分析
该研究从公共卫生视角评估以对比增强乳腺X线摄影(CESM)替代对比增强磁共振(CE-MRI)用于乳腺癌局部分期的成本影响。在苏格兰,大型健康委员会(年诊断≥500例癌症)年节省£64,069至£81,570,小型健康委员会(<500例)节省£6,453至£23,953。节省额度最敏感于年检查量和现有乳腺X线机能否升级为CESM。结论认为转换可能节省成本,但亟需研究证实CESM对CE-MRI在局部分期中的非劣效性。
要点
- CESM替代CE-MRI用于乳腺癌局部分期在苏格兰大、小健康委员会均可能节省成本。
- 成本节省最敏感因素为年检查量及现有乳腺X线机能否升级为CESM。
- CESM对CE-MRI的局部分期非劣效性尚未证实,需进一步研究。
核心结论
- 以CESM替代CE-MRI用于乳腺癌局部分期对苏格兰大、小健康委员会均可能节省成本。
研究设计与样本
- 成本分析研究,从公共卫生视角比较CE-MRI与CESM用于乳腺癌局部分期的成本。
- CE-MRI成本取自NHS参考成本;CESM成本采用自下而上法计算,含机器使用、泵注射器、对比剂、图像存储及人员报告和插管时间分配。
- 现有机器升级为CESM或购买新乳腺X线机的成本通过国家采购获取;其他成本来自当地药房、已发表单位成本数据或基于调查的估计。
诊断标准与关键数值
- 大型健康委员会(年诊断≥500例癌症)从CE-MRI转换为CESM的成本节省范围为£64,069至£81,570。
- 小型健康委员会(年诊断<500例癌症)从CE-MRI转换为CESM的成本节省范围为£6,453至£23,953。
临床应用与阅片要点
- 在规划乳腺癌局部分期影像服务时,可参考本成本分析评估以CESM替代CE-MRI的经济可行性。
- 成本节省受年检查量和现有乳腺X线机能否升级为CESM影响,需结合本地情况评估。
局限性
- CESM对CE-MRI作为局部分期技术的非劣效性尚未证实,亟需进一步研究。
- 分析输入数据可在非劣效性结果可用时更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To assess the cost impact of switching from contrast-enhanced magnetic resonance imaging (CE-MRI) to contrast-enhanced spectral mammography (CESM) for loco-regional staging of breast cancer from a public healthcare perspective.
MATERIALS AND METHODS: The CE-MRI cost was obtained from the NHS reference cost. The CESM cost was calculated using a bottom-up approach including use of the machine, pump injector, contrast medium, image storage, and time allocation for staff reporting and cannulation. The cost of upgrading existing machines to CESM or purchasing new mammographic machines was obtained via national procurement. Other costs were obtained from local pharmacy, published unit cost data, or estimated based on surveys.
RESULTS: For large health boards in Scotland (≥500 cancers diagnosed per annum), the cost savings of switching from CE-MRI to CESM range from £64,069 to £81,570. For small health boards (<500 cancers diagnosed per annum), the cost savings of switching from CE-MRI to CESM range from £6,453 to £23,953. The cost savings are most sensitive to the number of tests conducted per year, and whether the existing mammography machine can be upgraded to CESM or not.
CONCLUSION: Switching from CE-MRI to CESM for loco-regional staging of breast cancer is likely to be cost saving for both large and small health boards in Scotland. Further research is urgently needed to confirm the non-inferiority of CESM to CE-MRI as a locoregional staging technique. The input data of this analysis can be updated when such results become available.
引用
- Savaridas, Jin. Costing analysis to introduce a contrast-enhanced mammography service to replace an existing breast MRI service for local staging of breast cancer. Clin Radiol. 2023. PMID: 36804270. doi:10.1016/j.crad.2023.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。